院前全血复苏用于创伤性失血性休克的疗效与安全性:系统评价与荟萃分析
该系统评价与荟萃分析纳入3项RCT、共2048例需院前输血的成人创伤性失血性休克患者(主要分析人群1695例),比较院前全血与标准成分血治疗。主要终点24小时全因死亡率无显著差异(OR 1.12,95%CI 0.81–1.55,p=0.49),28–30天死亡率、24小时内大量输血及血栓栓塞并发症亦均无显著差异,所有CI跨过无效线,异质性I2=0%。作者结论为汇总随机证据未显示全血较成分血有死亡率获益,但因仅3项规模与质量有限的试验,需谨慎解读并等待足够把握度的RCT确认。
要点
- 成人创伤性失血性休克院前全血 vs 成分血:24小时全因死亡率OR 1.12(95%CI 0.81–1.55,p=0.49),无显著差异。
- 28–30天死亡率OR 1.15(95%CI 0.90–1.47,p=0.28),同样无显著差异。
- 24小时内大量输血OR 1.09(95%CI 0.80–1.50),血栓栓塞并发症(深静脉血栓、肺栓塞、缺血性卒中)亦无显著差异,CI均跨无效线。
- 全部合并分析I2=0%,但仅3项RCT、样本量有限且质量受限,结论需谨慎。
- 既往观察性证据多为全血对比晶体液或未输血,而非对比成分血,本随机证据是对该信号的修正而非推翻。
适用人群与场景
- 成人创伤性失血性休克、需院前输血的患者(3项RCT,随机2048例,主要分析人群1695例)。
- 排除:非随机研究、非创伤性出血、战斗伤员。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,仅纳入RCT(3项,随机2048例,主要分析人群1695例),排除非随机研究、非创伤性出血及战斗伤员。
- 干预与对照:院前全血(WB) vs 标准成分血治疗(BC)。
- 主要终点:24小时全因死亡率OR 1.12(95%CI 0.81–1.55,p=0.49),无显著差异。
- 关键次要终点:28–30天死亡率OR 1.15(95%CI 0.90–1.47,p=0.28);24小时内大量输血OR 1.09(95%CI 0.80–1.50);血栓栓塞并发症(深静脉血栓、肺栓塞、缺血性卒中)无显著差异,所有CI跨无效线。
- 异质性:I2=0%。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,仅纳入RCT;采用Cochrane RoB 2工具评估偏倚风险(必要时用集群随机变体)。
- 局限:仅3项试验、规模与质量有限,作者明确提示需谨慎解读,并需足够把握度的RCT确认及识别最可能获益的亚组。
- 观察性证据多为全血对比晶体液或未输血而非成分血,故本随机数据为修正而非推翻既有信号。
对床旁实践的改变
- 对成人创伤性失血性休克,院前使用全血不应被理解为较成分血有已证实的死亡率获益;现有随机证据未显示24小时或28–30天死亡率优势。
- 院前全血与成分血在24小时内大量输血及血栓栓塞并发症方面亦无显著差异,选择时可结合可用性与流程,而非依据死亡率获益预期。
- 证据仅来自3项规模与质量有限的RCT,不能外推至非创伤性出血、战斗伤员或儿童;原文未提供具体亚组获益人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy and safety of prehospital whole blood (WB) resuscitation compared with the standard care blood components (BC) in adult patients with traumatic haemorrhagic shock.
METHODS: We included RCTs of adult patients with traumatic haemorrhagic shock requiring prehospital blood; non-randomised studies, non-traumatic haemorrhage, and combat casualties were excluded. PubMed/MEDLINE, CENTRAL, Embase, Scopus, the Web of Science, and ClinicalTrials.gov were searched from inception to 20 May 2026. Two reviewers assessed risk of bias using the Cochrane RoB 2 tool (cluster-randomised variant where appropriate). Dichotomous outcomes were pooled as odds ratios by generic inverse-variance under a random-effects model. The primary outcome of this review was all-cause mortality at 24 h after randomisation.
RESULTS: Three RCTs met the eligibility criteria, randomising 2048 patients (1695 in the trials' primary-analysis populations). Prehospital WB did not differ significantly from BC in 24-h all-cause mortality (OR 1.12, 95% CI 0.81-1.55; p = 0.49) or 28-30-day mortality (OR 1.15, 95% CI 0.90-1.47; p = 0.28). Massive transfusion within 24 h (OR 1.09, 95% CI 0.80-1.50) and thromboembolic complications (deep-vein thrombosis, pulmonary embolism, and ischaemic stroke) likewise showed no significant difference, with all confidence intervals crossing the null. Statistical heterogeneity was absent throughout (I2 = 0%).
CONCLUSION: Among adults with traumatic haemorrhagic shock, pooled randomised evidence showed no significant mortality benefit for prehospital whole blood over standard blood-component therapy. Because much of the observational evidence compared whole blood with crystalloid or no transfusion rather than with components, these randomised data refine rather than overturn that signal. Given only three trials of limited size and quality, the findings warrant caution, and adequately powered randomised trials are needed to confirm them and to identify the subgroups most likely to benefit.
参考来源
- Khan YY, Alzahrani AA, Alghamdi RS, et al. Efficacy and safety of prehospital whole blood resuscitation in traumatic haemorrhagic shock a systematic review and meta-analysis. Am J Emerg Med. 2026. PMID: 42526297. doi:10.1016/j.ajem.2026.07.040
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。